David Dingli

30.9k total citations · 3 hit papers
465 papers, 14.8k citations indexed

About

David Dingli is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, David Dingli has authored 465 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 297 papers in Hematology, 223 papers in Molecular Biology and 158 papers in Oncology. Recurrent topics in David Dingli's work include Multiple Myeloma Research and Treatments (218 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (116 papers) and Protein Degradation and Inhibitors (65 papers). David Dingli is often cited by papers focused on Multiple Myeloma Research and Treatments (218 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (116 papers) and Protein Degradation and Inhibitors (65 papers). David Dingli collaborates with scholars based in United States, Portugal and Germany. David Dingli's co-authors include Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Shaji Kumar, Francis K. Buadi, Stephen J. Russell, Suzanne R. Hayman, S. Vincent Rajkumar, Robert A. Kyle and John A. Lust and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

David Dingli

439 papers receiving 14.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved survival in multiple myeloma and the impact of novel therapies

2007 1.7k citations Shaji Kumar, S. Vincent Rajkumar et al. Blood profile →
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

2013 957 citations Shaji Kumar, Angela Dispenzieri et al. Leukemia profile →
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

2012 730 citations Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Dingli United States	64	8.9k	8.0k	5.3k	2.7k	2.1k	465	14.8k
Jerry A. Katzmann United States	54	5.1k 0.6×	5.4k 0.7×	2.6k 0.5×	2.6k 1.0×	515 0.3×	171	10.6k
Andrew W. Roberts Australia	67	7.6k 0.8×	5.5k 0.7×	5.0k 0.9×	4.9k 1.8×	801 0.4×	275	17.4k
Jaroslaw P. Maciejewski United States	78	6.9k 0.8×	11.7k 1.5×	2.2k 0.4×	6.2k 2.3×	1.5k 0.7×	678	21.1k
Hans Kreipe Germany	63	5.6k 0.6×	1.5k 0.2×	4.5k 0.8×	1.6k 0.6×	925 0.4×	426	13.6k
Frits van Rhee United States	63	6.6k 0.7×	9.9k 1.2×	6.4k 1.2×	2.0k 0.7×	357 0.2×	421	14.0k
Régis Bataille France	71	8.5k 1.0×	10.0k 1.2×	7.5k 1.4×	2.5k 0.9×	678 0.3×	269	16.9k
Attilio Orazi United States	49	4.5k 0.5×	8.8k 1.1×	2.8k 0.5×	6.8k 2.5×	771 0.4×	281	16.1k
Jean‐Luc Harousseau France	69	8.8k 1.0×	11.0k 1.4×	7.0k 1.3×	2.6k 1.0×	468 0.2×	319	15.8k
Alberto Órfão Spain	66	4.5k 0.5×	5.4k 0.7×	3.1k 0.6×	3.4k 1.2×	584 0.3×	463	16.1k
Robert P. Hasserjian United States	48	4.6k 0.5×	9.3k 1.2×	2.9k 0.5×	6.3k 2.3×	706 0.3×	285	16.2k

Countries citing papers authored by David Dingli

Since Specialization

Citations

This map shows the geographic impact of David Dingli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Dingli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Dingli more than expected).

Fields of papers citing papers by David Dingli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Dingli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Dingli. The network helps show where David Dingli may publish in the future.

Co-authorship network of co-authors of David Dingli

This figure shows the co-authorship network connecting the top 25 collaborators of David Dingli. A scholar is included among the top collaborators of David Dingli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Dingli. David Dingli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barreto, Jason N., A. Kosobud, Prashant Kapoor, et al.. (2025). Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization. JCO Oncology Practice. 22(1). 83–90. 1 indexed citations

Binder, Moritz, Joselle Cook, Morie A. Gertz, et al.. (2025). Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma. Leukemia. 39(4). 1005–1008. 1 indexed citations

Latour, Régis Peffault de, Austin Kulasekararaj, David Dingli, et al.. (2025). Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria. European Journal Of Haematology. 115(2). 125–133.

Bansal, Radhika, Hassan B. Alkhateeb, Stephen M. Ansell, et al.. (2024). Metformin and cytokine release syndrome after immune effector cell therapy.. Journal of Clinical Oncology. 42(16_suppl). e14535–e14535.

Dingli, David, et al.. (2024). Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates. Blood. 144(Supplement 1). 5680–5680. 1 indexed citations

Vaxman, Iuliana, Shaji Kumar, Angela Dispenzieri, et al.. (2024). Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM. British Journal of Haematology. 206(2). 607–614. 1 indexed citations

Waheed, Anem, Jamile M. Shammo, & David Dingli. (2023). Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape. Blood Reviews. 64. 101158–101158. 9 indexed citations

Bansal, Radhika, Jeremy T. Larsen, Matthew Hathcock, et al.. (2023). Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer Journal. 13(1). 47–47. 13 indexed citations

Bansal, Radhika, Jeremy T. Larsen, Matthew Hathcock, et al.. (2022). Prognostic Value of Early Bone Marrow MRD Status in CAR-T Therapy for Myeloma. Transplantation and Cellular Therapy. 28(3). S186–S187. 2 indexed citations

10.

Lenaerts, Tom, et al.. (2021). Multistage feedback-driven compartmental dynamics of hematopoiesis. iScience. 24(4). 102326–102326. 3 indexed citations

11.

Ho, Matthew, Saurabh Zanwar, Prashant Kapoor, et al.. (2021). The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer Journal. 11(9). 158–158. 6 indexed citations

12.

Hwa, Yi L., Martha Q. Lacy, Morie A. Gertz, et al.. (2020). Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal Of Haematology. 106(3). 433–436. 2 indexed citations

13.

Saleh, Abdullah S. Al, M Hasib Sidiqi, Eli Muchtar, et al.. (2019). Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation. 25(8). 1520–1525. 7 indexed citations

14.

Saleh, Abdullah S. Al, M Hasib Sidiqi, Surbhi Sidana, et al.. (2019). Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology. 94(10). 1066–1071. 13 indexed citations

15.

Sidana, Surbhi, M Hasib Sidiqi, Angela Dispenzieri, et al.. (2019). Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology. 94(9). 1020–1026. 31 indexed citations

16.

Lenaerts, Tom, et al.. (2018). Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria. PLoS Computational Biology. 14(6). e1006133–e1006133. 14 indexed citations

17.

Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535. 120 indexed citations

18.

Reeder, Craig B., Shaji Kumar, M. Q. Lacy, et al.. (2011). A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology. 156(3). 326–333. 35 indexed citations

19.

Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014. 226 indexed citations

20.

Dingli, David, Brad Kemp, Michael K. O’Connor, et al.. (2005). Combined I-124 Positron Emission Tomography/Computed Tomography Imaging of NIS Gene Expression in Animal Models of Stably Transfected and Intravenously Transfected Tumor. Molecular Imaging and Biology. 8(1). 16–23. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact